Source: Google NewsPublished on 2020-12-21
Related Articles:
- Revive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin Program - GlobeNewswire December 21, 2020 Revive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin Program GlobeNewswire
- PharmaTher Files U.S. Patent for Novel Combinations of Psilocybin and FDA Approved Drugs to Treat Neurological Disorders - GlobeNewswire December 15, 2020 PharmaTher Files U.S. Patent for Novel Combinations of Psilocybin and FDA Approved Drugs to Treat Neurological Disorders GlobeNewswire
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
- Silo Pharma Plans Phase 2B Trial Testing Low-dose Psychedelics in Parkinson’s December 4, 2020 Silo Pharma is collaborating with Maastricht University on a Phase 2b clinical trial to investigate the effects of low-dose psychedelics on cognitive and emotional dysfunction in patients with Parkinson’s disease. “The signing of this clinical study agreement represents a significant milestone for the Company as we continue our work to bring novel therapeutics to patients in need,” Eric Weisblum, chairman…
- Man fights for legalization of medical psilocybin mushroom - Omak Okanogan County Chronicle March 26, 2019 Man fights for legalization of medical psilocybin mushroom Omak Okanogan County ChronicleSPOKANE - Darren McCrea is fighting for legalization of psilocybin mushrooms, federally listed as a Schedule 1 drug with no accepted medical value or use.
- Monthly Research Review – September 2019 September 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease - GlobeNewswire December 8, 2020 PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease GlobeNewswire
- PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson's Disease - GlobeNewswire December 10, 2020 PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson's Disease GlobeNewswire
- PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease - GlobeNewswire December 8, 2020 PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease GlobeNewswire
- PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease - GlobeNewswire December 8, 2020 PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease GlobeNewswire
- PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease - GlobeNewswire December 8, 2020 PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease GlobeNewswire
- PharmaTher Announces Application for OTCQB Listing Canadian Stock Exchange:PHRM.CN - GlobeNewswire December 30, 2020 PharmaTher Announces Application for OTCQB Listing Canadian Stock Exchange:PHRM.CN GlobeNewswire
- Monthly research review – October 2019 October 31, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Sio Gene Therapies to Sell Arvelle Stake as Part of Angelini Pharma's Acquisition of Arvelle Therapeutics - GlobeNewswire January 4, 2021 Sio Gene Therapies to Sell Arvelle Stake as Part of Angelini Pharma's Acquisition of Arvelle Therapeutics GlobeNewswire
- Noticing the Signs of Parkinson’s Disease in a Loved One August 6, 2018 If you were to go to a Parkinson’s disease website, you’d probably find a post on signs and symptoms of PD. The problem is that it can be hard to notice the signs if you are the one with Parkinson’s disease. You may have grown so used to the symptoms that you no longer take them as something serious. I’ve…
- 2019: Year in review December 31, 2019 In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
- When Bluerock became Bayer August 18, 2019 Cell replacement therapy is a key component of any “cure” for Parkinson’s – replacing the cells that have been lost over the course of the condition. Cell transplantation of dopamine neurons has a long track record of both preclinical and clinical development and represents the most developed of the cell replacement approaches. Two weeks ago, the biotech firm BlueRock…
- Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. October 30, 2019 Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. BMC Psychiatry. 2019 Oct 28;19(1):321 Authors: Dos Santos RG, Bouso JC, Hallak JEC Abstract In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional…
- Center of Excellence Series: The Fresco Institute at NYU Langone Medical Center’s Social Work for Parkinson’s Program June 29, 2017 “The experience of living with Parkinson’s disease (PD) is unique to each individual. We really strive to listen to our patients, caregivers, families, providers and the community in creating an all-encompassing supportive services program that helps people to adapt and live well with Parkinson’s across the continuum and at all stages of the disease,” said Amy Lemen, MA, LCSW. “One…
- Evaluation of oxidative stress mechanisms and the effects of phytotherapic extracts on Parkinson's disease Drosophila PINK1B9 model. July 12, 2019 Evaluation of oxidative stress mechanisms and the effects of phytotherapic extracts on Parkinson's disease Drosophila PINK1B9 model. FASEB J. 2019 Jul 10;:fj201901010 Authors: Baroli B, Loi E, Solari P, Kasture A, Moi L, Muroni P, Kasture S, Setzu MD, Liscia A, Zavattari P Abstract Oxidative stress is commonly observed in both idiopathic and genetic cases of Parkinson's disease (PD). It…